Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchNo recent work listed

David William Hedley

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1323-2655; OpenAlex author ID A5011309882; NIH RePORTER profile ID 11402533. Sources: OpenAlex.

Their work

Papers
34 (first author 1, last author 11)
Trials
0
Grants
1
Labs led
1
Collaborators
73
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 3 papers, 1 grant · 2015: 4 papers · 2016: 6 papers · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: 3 papers

Papers 34

  1. Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell-derived IL-6 is reversed predominantly by IL-6 blockade. Co-author DOI 10.1016/j.jcyt.2021.12.005↗
  2. Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic Cancer. Last author DOI 10.1021/acsptsci.2c00170↗
  3. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-22-86↗
  4. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Co-author DOI 10.1126/sciadv.abf7114↗
  5. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab')2 alone or combined with radiosensitizing gemcit… Co-author DOI 10.1016/j.nucmedbio.2020.02.001↗
  6. Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy. Last author DOI 10.1038/s41598-019-57364-0↗
  7. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-parti… Co-author DOI 10.1186/s41181-020-00111-y↗
  8. Pharmacokinetic Analysis of Dynamic [18F]FAZA PET Imaging in Pancreatic Cancer Patient Co-author DOI 10.21203/rs.3.rs-39968/v1↗
  9. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  10. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu. Co-author DOI 10.1021/acs.molpharmaceut.8b01040↗
  11. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1007/s10897-018-0212-1↗
  12. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.7b01000↗
  13. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  14. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  15. EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG2K Chains for MicroPET/CT Imaging of Patient-Derived Pancreatic Cancer Xenografts. Co-author DOI 10.1021/acsbiomaterials.6b00649↗
  16. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Last author DOI 10.18632/oncotarget.13619↗
  17. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. First author DOI 10.1007/s00280-016-3102-y↗
  18. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Co-author DOI 10.1038/bjc.2016.222↗
  19. Cytokinetic effects of Wee1 disruption in pancreatic cancer. Last author DOI 10.1080/15384101.2016.1138188↗
  20. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts. Last author DOI 10.1371/journal.pone.0167272↗
  21. Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.11060↗
  22. Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake. Last author DOI 10.2967/jnumed.115.167650↗
  23. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F… Co-author DOI 10.1016/j.nucmedbio.2014.10.009↗
  24. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Last author DOI 10.1038/bjc.2015.220↗
  25. Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. Last author DOI 10.1038/bjc.2015.284↗
  26. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2014.59.7401↗
  27. Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer. Co-author DOI 10.1016/j.clon.2014.01.003↗
  28. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2014.04.008↗
  29. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Co-author DOI 10.1038/bjc.2014.418↗
  30. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. Last author DOI 10.1002/ijc.28006↗
  31. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Co-author DOI 10.1007/s10637-010-9611-3↗
  32. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Co-author DOI 10.1007/s10637-011-9673-x↗
  33. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Last author DOI 10.1371/journal.pone.0041102↗
  34. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Last author DOI 10.1158/0008-5472.can-10-4049↗

Grants 1

  1. Stromal depletion for pancreatic cancer therapy R21CA176339↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Neesha C. Dhani · 10 shared papers, 2014–2022 · strength 0.67
  2. Raymond M. Reilly · 6 shared papers, 2015–2020 · strength 0.64
  3. Steve Gallinger · 11 shared papers, 2014–2022 · strength 0.64
  4. Mitchell A. Winnik · 5 shared papers, 2015–2020 · strength 0.51
  5. Malcolm J. Moore · 9 shared papers, 2012–2018 · strength 0.40
  6. Jennifer Jane Knox · 5 shared papers, 2016–2022 · strength 0.37
  7. Sadaf Aghevlian · 3 shared papers, 2018–2020 · strength 0.37
  8. Yijie Lu · 3 shared papers, 2017–2019 · strength 0.30
  9. Qing Chang · 3 shared papers, 2013–2022 · strength 0.29
  10. Robert C. Grant · 5 shared papers, 2015–2019 · strength 0.28
  11. Amanda J. Boyle · 3 shared papers, 2015–2020 · strength 0.28
  12. Faiyaz Notta · 4 shared papers, 2017–2021 · strength 0.26
  13. Ayelet Borgida · 4 shared papers, 2015–2019 · strength 0.23
  14. Sandra Elisabeth Fischer · 3 shared papers, 2018–2022 · strength 0.23
  15. Edward Taylor · 2 shared papers, 2020 · strength 0.22
  16. Spring Holter · 4 shared papers, 2014–2018 · strength 0.22
  17. Ines Lohse · 3 shared papers, 2015–2017 · strength 0.19
  18. Roula Antoon · 1 shared paper, 2022 · strength 0.19
  19. Armand Keating · 1 shared paper, 2022 · strength 0.19
  20. Jason Moffat · 2 shared papers, 2016–2021 · strength 0.18
  21. Francesco Gabriele Tatangelo Fazzari · 1 shared paper, 2022 · strength 0.17
  22. Kyaw Lwin Aung · 2 shared papers, 2018–2022 · strength 0.17
  23. Daniel John Renouf · 4 shared papers, 2012–2016 · strength 0.17
  24. Ashton Anthony Connor · 3 shared papers, 2017–2019 · strength 0.15
  25. Stefano Serra · 3 shared papers, 2015–2019 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.